Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose

Loading news article.

Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose | WAPE

Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose

Article summary

Related companies

Comments —